As­traZeneca drops an OX40 can­cer drug can­di­date in Q4 pipeline cleanup

Q4 may have been a tri­umph in many re­spects, as As­traZeneca’s can­cer drugs con­tin­ue to carve out a big­ger fran­chise for the com­pa­ny — cru­cial for its fu­ture. But there were al­so some big set­backs as the R&D group con­tin­ues to hit and miss with its tri­als. 

The biggest pipeline set­backs came with the fail­ure of Imfinzi and treme­li­mum­ab in two com­bo stud­ies aimed at lung and head and neck can­cer, which we re­port­ed ear­li­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.